Desulfovibrio fairfieldensis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Desulfovibrio fairfieldensis is a Gram-negative, non-spore-forming, strictly anaerobic, motile, vibrio bacterium. It has been detected in at least 8 gut microbiome compilation studies or metastudies. The DNA G+C content is 62%. Desulfovibrio fairfieldensis is probably a common, although minor, coloniser of the gut. (Tee1996)



  • This organism has been recovered from clinical sources (blood - CCUG) and human faeces. Is a rare opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Tee1996);
    Character Response
  • 🧂
  • Salt tolerance:
  • tolerates 3% salt;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 25℃; grows at 37℃; grows at 42℃;
  • Active enzymes:
  • alkaline phosphatase; acid phosphatase; catalase; esterase C4; esterase lipase C8; naphthol-ASBI-P;
    • SPECIAL FEATURES (Tee1996);
    Character Response
  • ✓
  • Metabolites produced:
  • Hâ‚‚S;
  • ✗
  • Nitrite:
  • not reduced
  • ✓
  • Sulfate:
  • reduced
  • ✓
  • Thiosulfate:
  • reduced
  • Pigments:
  • fluorescent
    • RESPONSE TO ANTIBIOTICS (Tee1996); (Goldstein2018a); (Tyrrell2012); (Goldstein2006);
    Class Active Resistant
  • Penicillins:
  • ampicillin-sulbactam; imipenem;
  • penicillin; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin;
  • Tetracyclines:
  • tigecycline;
  • Quinolines:
  • ciprofloxacin;
  • Heterocycles:
  • metronidazole;
  • chloramphenicol;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;
  • daptomycin; linezolid;
  • NOTES

    Gibson et al. (6, 11, 12), in a number of reports,
    implied a possible pathogenic role for Desulfovibrio spp. in
    ulcerative colitis in humans. So far, four cases of human infection
    with Desulfovibrio spp. have been documented

    The source of infection in this case was probably the gastrointestinal
    tract. Conditions causing inflammation of the colon
    and portal pyelophlebitis, including inflammatory bowel disease
    or other pathology such as diverticulitis, are the most
    frequent sources of anaerobes in liver abscesses

  • Loubinoux, J., Bronowicki, J.-P., Pereira, I. A. C., Mougenel, J.-L., & Faou, A. E. (2002). Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiology Ecology, 40(2), 107–112.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Deltaproteobacteria Order:  Desulfovibrionales Family:  Desulfovibrionaceae Genus:  Desulfovibrio Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Swimming Morphology:  Vibrio Pigment:  fluorescent
    Health:  Unknown
    Source:  clinical sources (blood - CCUG) and human faeces
    DNA G+C(%):  62
    Lower T(℃):  25(neg)
    Mid T(℃):  37(+)
    High T(℃):  42(+)
    NaCl 3-5%:  3(+)
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + AlkalineP:  + AcidP:  + Esterase(C4):  + EstLip(C8):  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  + Pigment:  fluorescent
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  Var(MIC50): 1, MIC90: >32, RNG: (0.125–>32)
    amp-sulb:  S(MIC50): 2, MIC90: 4, RNG: (2–4)
    penicillin:  R(>256)
    piper-taz:  R(MIC50): 64, MIC90: >64, RNG: (64–>64)
    imipenem:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25–0.5)
    cefoxitin:  R(MIC50): 64, MIC90: 128, RNG: (1–128)
    linezolid:  R(MIC50): 16, MIC90: >32, RNG: (2–>32)
    ciprofloxacin:  R(>32)
    levofloxacin:  Var(MIC50): 0.5, MIC90: >16, RNG: (0.06–>16)
    moxifloxacin:  Var(MIC50): 0.25, MIC90: 8, RNG: (0.25–>16)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tigecycline:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.125–0.5)
    vancomycin:  R(MIC50): >32, MIC90: >32, RNG: (>32)
    chloramphenicol:  R(>8)
    metronidazole:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125–0.25)
    clindamycin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.25–>32)
    daptomycin:  R(MIC50): >32, MIC90: >32, RNG: (>32)

    References

    SPECIFIC REFERENCES FOR DESULFOVIBRIO FAIRFIELDENSIS
  • Tee1996 - Probable new species of Desulfovibrio isolated from a pyogenic liver abscess.
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR DESULFOVIBRIO FAIRFIELDENSIS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Jeong2021 - The effect of taxonomic classification by full-length 16S rRNA sequencing with a synthetic long-read technology
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Minerbi2019 - Altered microbiome composition in individuals with fibromyalgia
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • ...............................
    • Added: April 08, 2021